Clinical Guides
Rheumatoid Arthritis
An India-contextualised, clinically focused guide to recognising inflammatory polyarthritis early, confirming a clinical diagnosis, starting disease-modifying care safely and coordinating specialist follow-up.
MedNext Academy | 12 min read
Rheumatoid Arthritis
An India-contextualised, clinically focused guide to recognising inflammatory polyarthritis early, confirming a clinical diagnosis, starting disease-modifying care safely and coordinating specialist follow-up.
Summary
Rheumatoid arthritis (RA) is a chronic immune-mediated inflammatory disease in which persistent synovitis can damage cartilage, bone, tendons and adjacent structures. Typical disease is a symmetrical small-joint polyarthritis, but early RA can be oligoarticular, seronegative or accompanied by constitutional symptoms. Pain alone is not RA: the clinical problem is demonstrable synovitis, its pattern, duration and consequences. Untreated inflammation can produce erosions, deformity, disability and extra-articular disease, while cardiovascular, bone and mental-health risk add to its burden.
The important management principle is early, shared, treat-to-target disease modification. Once a clinician has made the diagnosis, a conventional synthetic DMARD, commonly methotrexate when suitable, should not wait for erosions. Disease activity and function are measured repeatedly, therapy is adjusted toward remission or low activity, and analgesia never substitutes for disease control. The diagnosis, drug choice and safety monitoring need rheumatology supervision; this educational draft is not a prescription or approval to start immunosuppression.
How Common Is It?
RA occurs worldwide and is more often recorded in women, but a single prevalence number is misleading because methods, age structures, classification rules and access to rheumatology vary. Population surveys based on self-report, hospital registries and classification-criteria studies describe different populations. Incidence rises with age but disease can begin in young adults; delayed presentation makes prevalence appear larger where established disease accumulates. Seropositive and seronegative disease share clinical relevance, and absence of rheumatoid factor does not make a painful swollen-joint syndrome benign.
Indian burden is heterogeneous across urban, rural and tribal settings. Nationally representative contemporary prevalence and treatment-coverage estimates are limited, so imported figures should not be quoted as district facts. The visible burden includes lost work, care-giving dependence, deformity, depression, cardiovascular risk and out-of-pocket monitoring or biologic costs. A local service should count patients with active synovitis, time from symptoms to DMARD, remission or low-disease-activity status, infections, missed monitoring and functional outcomes. Such measures expose delays that a prevalence statistic cannot correct.
Risk Factors
RA arises from an interaction of immune susceptibility and exposures; no test predicts an individual future case with certainty. Family history modestly raises probability, but it does not justify screening well relatives with autoantibodies in ordinary practice. Cigarette smoking is a modifiable association, particularly for anti-citrullinated-protein-antibody-positive RA, and cessation is part of management rather than a moral judgement. Periodontal disease, obesity, occupational exposures and reproductive or hormonal factors have been investigated, but they do not diagnose RA or explain every patient.
Poor outcome is more likely with high disease activity, persistent swollen joints, early erosions, rheumatoid factor or ACPA positivity, extra-articular disease and delayed effective treatment. Infection exposure, diabetes, chronic kidney or liver disease, lung disease, pregnancy plans, alcohol intake, vaccination gaps and unreliable laboratory access are treatment-risk factors. They should shape a safer regimen and monitoring plan, not be used to withhold referral. Before advanced therapy in India, tuberculosis and hepatitis assessment is especially important; a screening result needs clinical interpretation and active infection must be excluded.
Diagnosis
RA is a clinical diagnosis supported by examination, laboratory testing and imaging. Classification criteria help standardise research but cannot replace a careful assessment, particularly in early or seronegative disease.
History
Establish onset, duration and evolution of joint swelling, pain and morning stiffness. Ask about hands, wrists and forefeet, functional tasks, nocturnal symptoms, fatigue, fever and weight change. Elicit psoriasis, uveitis, bowel symptoms, preceding infection, rashes, mouth ulcers, sicca symptoms, Raynaud phenomenon and family history. Record smoking, tuberculosis contact or symptoms, hepatitis risks, pregnancy intentions, medicines and occupation. A hot single joint, fever or abrupt severe pain changes the pathway.
Examination
Count tender and swollen joints rather than relying on a pain score. Examine MCP, PIP, wrists and MTP joints, shoulders, elbows, knees and ankles; look for synovial thickening, reduced range, effusion, tendon rupture, nodules, vasculitic skin change and compression neuropathy. Assess gait, grip, activities of daily living, blood pressure, weight, lungs, eyes, skin and neurological status. Document baseline function and an agreed disease-activity measure.
Investigations
Request ESR and CRP as inflammatory markers, full blood count, renal and liver tests for baseline safety, rheumatoid factor and ACPA when RA is suspected. Neither antibody proves RA nor does a negative result exclude it. Plain radiographs of hands and feet establish erosions and a baseline; ultrasound or MRI can demonstrate synovitis or early erosions when uncertainty remains. Aspirate an accessible acutely swollen joint for microscopy, culture and crystals before assuming a flare. Choose infection, connective-tissue, thyroid or other tests from the differential rather than ordering indiscriminate panels.
Differential Diagnosis
Psoriatic arthritis may be asymmetric, include distal joints, dactylitis, enthesitis or nail disease, but can resemble RA. Spondyloarthritis, lupus, Sjogren disease, viral arthritis, post-infectious arthritis and sarcoidosis can cause inflammatory polyarthritis. Acute symmetrical arthritis following chikungunya or other viral illness can persist in India; chronology, fever, rash, exposure and synovitis pattern matter, while positive autoantibodies can coexist and must not end reasoning.
Crystal arthritis can be polyarticular and septic arthritis can coexist with RA or immunosuppression. A hot joint, systemic illness or marked inflammatory response requires urgent aspiration and cultures. Osteoarthritis usually has bony enlargement and activity-related pain rather than prolonged inflammatory stiffness, though both conditions can coexist. Fibromyalgia increases tenderness and fatigue without objective synovitis; escalating DMARDs on tender-joint counts alone is unsafe. Consider hypothyroidism, haemochromatosis, parvovirus, tuberculosis, malignancy and drug reactions where history directs. The diagnostic label must be revised if the course, examination or response becomes inconsistent.
Management
Discuss diagnosis, prognosis, goals and uncertainty early. international and EULAR support a treat-to-target strategy: agree remission or low disease activity, measure progress frequently during active disease and change treatment if the target is not being reached. Education, occupational therapy, hand and foot support, graded exercise, physiotherapy, smoking cessation, weight and cardiovascular-risk care complement—not replace—DMARDs. Rest can be useful briefly in a severe flare, but sustained inactivity worsens weakness and function.
Begin a conventional synthetic DMARD promptly after diagnosis. Methotrexate is the usual anchor drug if not contraindicated; leflunomide or sulfasalazine are alternatives in appropriate patients. Short glucocorticoid bridging may control inflammation while a DMARD takes effect, but should have a recorded stop plan because cumulative toxicity is substantial. NSAIDs are symptom treatment only, at the lowest effective dose with individual gastrointestinal, renal and cardiovascular assessment. Inadequate response requires adherence and diagnosis review, then specialist escalation or combination treatment according to disease activity, prognostic features, comorbidity, licensing and affordability. Biologic and targeted synthetic DMARD decisions require infection screening and agent-specific risk assessment. Sustained remission may permit cautious dose reduction, not casual cessation.
Prescribing Information
Before methotrexate, document pregnancy status where relevant, contraception and conception plans, alcohol intake, liver and renal function, blood count, lung symptoms, interacting medicines and baseline infection risk. It is usually taken once weekly, never daily; write the day of week and folate plan clearly and provide a written toxicity and missed-dose plan. Mouth ulcers, severe nausea, new breathlessness, fever, bruising, jaundice or mucosal bleeding need urgent advice. Methotrexate is teratogenic and is not a drug to self-adjust. Monitoring intervals and dose follow local specialist protocol.
Leflunomide has important pregnancy, liver, blood-pressure and washout considerations. Sulfasalazine can affect blood counts and liver tests and requires counselling on allergy and reversible semen changes. Systemic steroids require glucose, blood-pressure, bone, eye, infection and adrenal-risk planning. Before biologic or JAK-pathway therapy, exclude serious infection, assess tuberculosis and viral hepatitis according to local protocol, update non-live vaccines where possible, obtain safety blood tests and discuss thrombosis, major cardiovascular event and malignancy risks relevant to the agent. Do not combine biologics casually or restart an interrupted immunosuppressant after sepsis without specialist advice.
When to Refer
Refer urgently to rheumatology for persistent synovitis of undetermined cause, especially when small joints of hands or feet, more than one joint, or symptoms exceeding three months are involved. Referral should not wait for rheumatoid factor, ACPA, an elevated CRP or radiographic erosion. Include onset, joint distribution, objective swelling, functional effect, acute-joint aspiration results if relevant, inflammatory markers, serology, imaging, comorbidities, infection risks, pregnancy plans and medicines already tried.
Same-day hospital assessment is needed for suspected septic arthritis, sepsis, acute neurovascular compromise or a severe systemic inflammatory illness. Expedite specialist input for rapidly progressive disability, recurrent flares despite a DMARD, drug toxicity, pregnancy planning, suspected interstitial lung disease, vasculitis, eye disease, cervical neurological symptoms or difficult infection screening. Refer to hand or orthopaedic surgery for tendon rupture, fixed deformity, severe joint destruction or persistent focal synovitis after medical optimisation. A multidisciplinary plan may require physiotherapy, occupational therapy, podiatry, respiratory, obstetric, dermatology, eye or mental-health services.
Red Flags
A feverish patient with a hot swollen joint must be treated as possible septic arthritis until aspiration, culture and clinical assessment establish otherwise. Immunosuppressed people may have muted fever or inflammatory markers. Rigors, hypotension, confusion, a new focal infection, rapidly spreading rash or breathlessness during DMARD treatment require urgent infection assessment rather than an automatic steroid increase. New cough, weight loss, drenching sweats or lymphadenopathy requires evaluation for tuberculosis or other infection before advanced immunosuppression.
Acute weakness, hand clumsiness, gait change, hyperreflexia, bladder disturbance or neck pain in established RA can indicate cervical spine instability or cord compression and needs urgent specialist imaging. Painful red eye or visual change may be scleritis or uveitis and needs prompt ophthalmic assessment. Digital ischaemia, purpura, mononeuritis, pleuritic breathlessness or haemoptysis may signal vasculitis, interstitial lung disease, embolism or another emergency. Severe cytopenia, jaundice, mucositis, bruising or new breathlessness during methotrexate treatment is medicine toxicity until assessed.
Indian Clinical Context
International international and EULAR pathways are useful evidence sources but are not Indian formulary, reimbursement or regulatory rules. Access to rheumatologists, ultrasound, regular laboratory monitoring, physiotherapy, biologics and JAK inhibitors differs sharply between districts and payment systems. A safe district plan identifies the named referral unit, affordable baseline tests, laboratory result-review owner, tuberculosis pathway, pharmacy supply and route back after adverse effects. It must not promise a biologic, insurance benefit or imaging service that is unavailable.
Tuberculosis is a central safety concern before substantial immunosuppression. Screen and investigate according to current National Tuberculosis Elimination Programme and institutional protocols, evaluating symptoms, examination, imaging and microbiology where active disease is plausible; immune-based tests do not independently rule in or rule out active TB. Viral hepatitis risk, vaccine history and local infection epidemiology also matter. Indian practice should use generic names, correct tablet strengths, written once-weekly methotrexate instructions and bilingual safety-netting where needed. Rehabilitation, work adaptation and family counselling may be as decisive as medicine availability. The NMC curriculum supports systematic assessment and appropriate consultation, not unsupervised specialist prescribing.
NMC Competency Mapping
The 2024 NMC CBME curriculum explicitly places rheumatoid arthritis within General Medicine Topic 7, Rheumatologic problems. GM7.1 addresses autoimmune mechanisms; GM7.2 to GM7.5 require a systematic approach to joint pain and distinction between inflammatory, mechanical and periarticular presentations. GM7.8 and GM7.9 support a discriminating history and examination of joints, muscle and skin. Learners should therefore recognise objective synovitis, document a joint pattern, distinguish arthralgia from arthritis and identify a hot joint needing aspiration.
GM7.10 to GM7.13 cover prioritised differential diagnosis, investigations, arthrocentesis and radiograph interpretation; GM7.14 to GM7.22 include explanation, treatment planning, DMARD principles, follow-up, quality-of-life impact and referral. Pharmacology competencies PH2.7 and PH2.8 support NSAID safety and rational arthritis drug plans. A student can present an inflammatory-polyarthritis case, interpret why antibody tests are supportive rather than definitive, counsel on methotrexate safety and justify urgent referral. This guide does not certify independent diagnosis, joint injection, DMARD initiation or biologic prescribing.
Key Exam Pearls for NEET PG
Classic RA is a symmetrical inflammatory polyarthritis involving MCP, PIP, wrist and MTP joints; DIP involvement suggests another diagnosis, although coexisting osteoarthritis is common. Morning stiffness and objective swelling support inflammation. Rheumatoid factor is not specific and ACPA is more specific, but seronegative RA exists. X-rays may show periarticular osteopenia, marginal erosions and joint-space narrowing; early films can be normal. The 2010 ACR/EULAR classification framework scores joint involvement, serology, acute-phase reactants and symptom duration, but classification is not a substitute for diagnosis.
Methotrexate is the anchor conventional DMARD and is weekly, with folate supplementation and laboratory monitoring. It is contraindicated in pregnancy and should not be confused with daily folic-acid dosing. Steroids bridge but do not replace DMARDs. RA complications include atlanto-axial instability, carpal tunnel syndrome, tendon rupture, nodules, vasculitis, interstitial lung disease, pleural disease, anaemia and increased cardiovascular risk. In an exam stem, a febrile hot joint in a person taking a DMARD is septic arthritis until proven otherwise; aspirate before assuming a flare. Treat-to-target means adjusting disease-modifying therapy toward remission or low activity through specialist follow-up.
For pattern recognition, rheumatoid nodules occur at pressure points in seropositive disease but are neither necessary nor diagnostic. Deformities are late consequences rather than requirements: ulnar deviation, swan-neck and boutonniere patterns arise from chronic synovitis, tendon imbalance and damage. Carpal tunnel symptoms arise from wrist synovitis. Knee effusion, Baker cyst and forefoot pain are common functional presentations. Cervical-spine symptoms or neurological signs require a separate urgent pathway. Extra-articular disease is more likely in severe, longstanding seropositive illness but should never be used to delay initial treatment.
Classify drugs carefully. Conventional synthetic DMARDs include methotrexate, leflunomide and sulfasalazine; biologic DMARDs target cytokines or cells; targeted synthetic DMARDs include JAK inhibitors. Biologics and JAK inhibitors are not interchangeable by class label because infection, cardiovascular, thrombosis, pregnancy and monitoring risks differ. A negative tuberculosis screen does not exclude active disease when symptoms or imaging are concerning. Avoid live vaccines during substantial immunosuppression unless a specialist has planned timing. In clinical questions, distinguish a drug adverse effect, disease flare and opportunistic infection before choosing escalation.
The practical examination sequence is inspection, palpation for synovial swelling, movement, function and documentation of tender and swollen joint counts. Pain on compression without swelling is not equivalent to synovitis. ESR and CRP measure inflammation imperfectly; serial assessment is more useful than an isolated value. Ultrasound can help distinguish active synovitis from tenosynovitis or effusion, but it does not remove the need for a coherent clinical diagnosis. In South Asian practice, retain infection, chikungunya, tuberculosis and crystal disease in the differential when epidemiology and history support them.
Pregnancy is not a reason to abandon disease control, but it changes medicine choices and needs pre-conception rheumatology-obstetric planning. Active inflammation itself can impair pregnancy outcomes and function. Some conventional DMARDs are compatible with carefully supervised pregnancy while methotrexate and leflunomide are not; do not select an answer by memorising a drug class without considering timing, washout and local specialist advice. During lactation, compatibility differs between agents. Another examination trap is assuming NSAIDs prevent erosion: they relieve pain but have no proven disease-modifying role. Long-term glucocorticoids can cause diabetes, hypertension, infection, cataract and osteoporosis, so the preferred strategy is timely DMARD optimisation and minimal steroid exposure. In a question about sustained remission, cautious tapering can be considered after a durable target, but abrupt discontinuation commonly risks flare.
Frequently Asked Questions
Can rheumatoid arthritis be diagnosed from a positive rheumatoid-factor result alone?
No. Rheumatoid factor can occur in other autoimmune diseases, chronic infection and some healthy people, while genuine RA can be seronegative. Diagnosis requires a compatible history, objective synovitis, distribution of joints, exclusion of important alternatives and supporting laboratory or imaging evidence. A positive result without clinical arthritis should not trigger DMARD treatment. Results are interpreted alongside age, phenotype, infection risk and longitudinal clinical assessment.
Why is methotrexate written as a once-weekly medicine rather than a daily tablet?
For inflammatory arthritis, methotrexate is normally administered once each week. Daily administration can cause life-threatening marrow, gastrointestinal and mucosal toxicity. Prescriptions should name the weekly day, tablet strength, folate plan, monitoring arrangement and whom to contact for fever, mouth ulcers, bruising, jaundice or breathlessness. Patients should repeat the weekly schedule back to the prescriber or pharmacist.
Does normal ESR or CRP exclude active rheumatoid arthritis?
No. Inflammatory markers support assessment and trend monitoring but can be normal in active disease, especially early or limited synovitis. Conversely they rise with infection and many other conditions. The joint examination, functional history and appropriate imaging remain central, and a normal result must not delay referral for persistent clinically suspicious swelling. Repeated normal results should prompt careful reassessment, not dismissal of observed synovitis.
What should a person taking a DMARD do when fever or a serious infection develops?
They should seek prompt clinical advice and tell the treating team exactly which medicines they take. Whether to hold or restart a DMARD depends on the infection, medicine, severity, laboratory results and recovery; it should not be guessed from an educational page. A hot joint, sepsis symptoms, breathlessness or tuberculosis symptoms needs urgent assessment. Carrying an updated medicine list improves emergency assessment and communication across services.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic